tbuckley/cabot-search huggingface dataset:
P1.09 Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation in NSCLC
Authors: D. Brocco, P. Lanuti, P. Simeone, G. Bologna, M. De Tursi, L. Irtelli, P. Di Marino, M. Peri, M. Marchisio, S. Miscia, N. Tinari
Journal: Journal of Thoracic Oncology (2019)
P1.19 Lung Cancer Screening Initiative and Identification of Novel Blood Biomarkers for Early Detection of Lung Cancer
Authors: S. Deb, A. Kuckovic, A. Anderson, J. Berei, S. Sreenivasappa, J. Ross, S. Martell, C. Vitali, W. Schulz, K.S. Racherla, N. Puri
Journal: Journal of Thoracic Oncology (2019)
OA03.03 Multi-Institutional Study of Pneumonitis After Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer
Authors: T. Sita, C. Hassanzadeh, R. Savoor, P. Samson, J. Bradley, M. Gentile, M. Roach, N. Mohindra, S. Waqar, C. Robinson, T. Kruser
Journal: Journal of Thoracic Oncology (2019)
Small molecules as theranostic agents in cancer immunology
Authors: Jindian Li, Juno Van Valkenburgh, Xingfang Hong, Peter S Conti, Xianzhong Zhang, Kai Chen
Journal: Theranostics (2019)

With further research into the molecular mechanisms and roles linking immune suppression and restraint of (pre)malignancies, immunotherapies have revolutionized clinical strategies in the treatment of cancer. However, nearly 70% of patients who received immune checkpoint therapeutics showed no response. Complementary and/or synergistic effects may occur when extracellular checkpoint antibody blockades combine with small molecules targeting intracellular signal pathways up/downstream of immune checkpoints or regulating the innate and adaptive immune response. After radiolabeling with radionuclides, small molecules can also be used for estimating treatment efficacy of immune checkpoint blockades. This review not only highlights some significant intracellular pathways and immune-related targets such as the kynurenine pathway, purinergic signaling, the kinase signaling axis, chemokines, etc., but also summarizes some attractive and potentially immunosuppression-related small molecule agents, which may be synergistic with extracellular immune checkpoint blockade. In addition, opportunities for small molecule-based theranostics in cancer immunology will be discussed.
PD01.19 Lung Cancer Strategist Program: a Novel Care Delivery Model to Improve Timeliness of Diagnosis and Treatment
Authors: W.W. Phillips, S.C. Hofferberth, J. Armitage, S. Fox, C. De Forcrand, P. Catalano, C. Lathan, J.S. Weissman, D.D. Odell, Y.L. Colson
Journal: Journal of Thoracic Oncology (2019)
A versatile imaging platform with fluorescence and CT imaging capabilities that detects myeloperoxidase activity and inflammation at different scales
Authors: Cuihua Wang, Benjamin Pulli, Negin Jalali Motlagh, Anning Li, Gregory R. Wojtkiewicz, Stephan P. Schmidt, Yue Wu, Matthias W.G. Zeller, John W. Chen
Journal: Theranostics (2019)

Aberrant innate immune response drives the pathophysiology of many diseases.Myeloperoxidase (MPO) is a highly oxidative enzyme secreted by activated myeloid pro-inflammatory immune cells such as neutrophils and macrophages, and is a key mediator of the damaging innate immune response.Current technologies for detecting MPO activity in living organisms are sparse and suffer from any combination of low specificity, low tissue penetration, or low spatial resolution.We describe a versatile imaging platform to detect MPO activity using an activatable construct conjugated to a biotin moiety (MPO-activatable biotinylated sensor, MABS) that allows monitoring the innate immune response and its modulation at different scales and settings.Methods: We designed and synthesized MABS that contains MPO-specific and biotin moieties, and validated its specificity and sensitivity combining with streptavidin-labeled fluorescent agent and gold nanoparticles imaging in vitro and in vivo in multiple mouse models of inflammation and infection, including Matrigel implant, dermatitis, cellulitis, cerebritis and complete Fraud's adjuvant (CFA)-induced inflammation.Results: MABS MPO imaging non-invasively detected varying MPO concentrations, MPO inhibition, and MPO deficiency in vivo with high sensitivity and specificity.MABS can be used to obtain not only a fluorescence imaging agent, but also a CT imaging agent, conferring molecular activity information to a structural imaging modality.Importantly, using this method on tissue-sections, we found that MPO enzymatic activity does not always co-localize with MPO protein detected with conventional techniques (e.g., immunohistochemistry), underscoring the importance of monitoring enzymatic activity.Conclusion: By choosing from different available secondary probes, MABS can be used to create systems suitable to investigate and image MPO activity at different scales and settings.
OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study
Authors: M.J. Hochmair, A. Morabito, D. Hao, C.-T. Yang, R.A. Soo, J.C.-H. Yang, R. Gucalp, B. Halmos, L. Wang, A. Märten, T. Cufer, C. Weinlinger
Journal: Journal of Thoracic Oncology (2019)
Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer
Authors: Toshiya Abe, Chiho Koi, Shiro Kohi, Ki-Byung Song, Koji Tamura, Anne Macgregor-Das, Naoki Kitaoka, Miguel Chuidian, Madeline Ford, Mohamad Dbouk, Michael Borges, Jin He, Richard Burkhart, Christopher L. Wolfgang, Alison P. Klein, James R. Eshleman, Ralph H. Hruban, Marcia Irene Canto, Michael Goggins
Journal: Clinical Gastroenterology and Hepatology (2019)

Levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and cancer antigen 125 (CA-125) in blood are used as markers to determine the response of patients with cancer to therapy, but are not used to identify patients with pancreatic cancer.We obtained blood samples from 504 patients undergoing pancreatic surveillance from 2002 through 2018 who did not develop pancreatic cancer and measured levels of the tumor markers CA19-9, CEA, CA-125, and thrombospondin-2. Single-nucleotide polymorphisms (SNPs) in FUT3, FUT2, ABO, and GAL3ST2 that have been associated with levels of tumor markers were used to establish SNP-defined ranges for each tumor marker. We also tested the association between additional SNPs (in FUT6, MUC16, B3GNT3, FAM3B, and THBS2) with levels of tumor markers. To calculate the diagnostic specificity of each SNP-defined range, we assigned the patients under surveillance into training and validation sets. After determining the SNP-defined ranges, we determined the sensitivity of SNP-adjusted tests for the tumor markers, measuring levels in blood samples from 245 patients who underwent resection for pancreatic ductal adenocarcinoma (PDAC) from 2010 through 2017.A level of CA19-9 that identified patients with PDAC with 99% specificity had 52.7% sensitivity. When we set the cut-off levels of CA19-9 based on each SNP, the test for CA19-9 identified patients with PDAC with 60.8% sensitivity and 98.8% specificity. Among patients with FUT3 alleles that encode a functional protein, levels of CA19-9 greater than the SNP-determined cut-off values identified 66.4% of patients with PDAC, with 99.3% specificity. In the validation set, levels of CEA varied among patients with vs without SNP in FUT2, by blood group, and among smokers vs nonsmokers; levels of CA-125 varied among patients with vs without the SNP in GAL3ST2. The use of the SNPs to define the ranges of CEA and CA-125 did not significantly increase the diagnostic accuracy of the assays for these proteins. Combining data on levels of CA19-9 and CEA, CA19-9 and CA-125, or CA19-9 and thrombospondin-2 increased the sensitivity of detection of PDAC, but slightly reduced specificity.Including information on SNPs associated with levels of CA19-9, CEA, and CA-125 can improve the diagnostic accuracy of assays for these tumor markers in the identification of patients with PDAC. Clinicaltrials.gov no: NCT02000089.
Logistical Challenges Associated With Implementing Precision Medicine
Authors: George A. Stouffer, Craig R. Lee
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Transcytosis - An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery
Authors: Xiangsheng Liu, Jinhong Jiang, Huan Meng
Journal: Theranostics (2019)

Numerous nano drug delivery systems have been developed for preclinical cancer research in the past 15 years with the hope for a fundamental change in oncology.The robust nanotherapeutic research has yielded early-stage clinical products as exemplified by the FDA-approved nano formulations (Abraxane ® for paclitaxel and Onyvide ® for irinotecan) for the treatment of solid tumors, including pancreatic ductal adenocarcinoma (PDAC).It is generally believed that enhanced permeability and retention (EPR) plays a key role in nanocarriers' accumulation in preclinical tumor models and is a clinically relevant phenomenon in certain cancer types.However, use of EPR effect as an across-the-board explanation for nanoparticle tumor access is likely over-simplified, particularly in the stroma rich solid tumors such as PDAC.Recently, ample evidences including our own data showed that it is possible to use transcytosis as a major mechanism for PDAC drug delivery.In this mini-review, we summarize the key studies that discuss how transcytosis can be employed to enhance EPR effect in PDAC, and potentially, other cancer malignancies.We also mentioned other vasculature engineering approaches that work beyond the classic EPR effect.
Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications
Authors: Nanja van Geel, Iltefat Hamzavi, Indermeet Kohli, Albert Wolkerstorfer, Henry W. Lim, Jung Min Bae, Harvey Lui, John E. Harris, Amit G. Pandya, Steven Thng Tien Guan, Marwa Abdallah, Samia Esmat, Julien Seneschal, Reinhart Speeckaert, Lynda Grine, Hee Young Kang, Noufal Raboobee, Leihong Flora Xiang, Marcel Bekkenk, Mauro Picardo, Alain Taieb
Journal: Journal of the American Academy of Dermatology (2019)
PD01.20 Medicaid Outcome Inequalities in Small Cell Lung Cancer
Authors: S. Chun, T. Pezzi, D. Schwartz, K. Pisters, A. Mohamed, J. Welsh, J. Chang, Z. Liao, S. Gandhi, L. Byers, B. Minsky, S. Hahn, C. Fuller
Journal: Journal of Thoracic Oncology (2019)
Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group
Authors: W S Richardson, A S Detsky
Journal: JAMA (1995)

YOU RECALL from the first of our two articles concerning clinical decision analysis<sup>1</sup>that your patient is a middle-aged man with heart failure from an idiopathic dilated cardiomyopathy. You are trying to decide whether to recommend anticoagulation with warfarin to prevent systemic or pulmonary thromboembolism. Your literature search showed that no randomized clinical trials of warfarin for this use have been published. The search did discover a clinical decision analysis,<sup>2</sup>and in the first article, we showed you how to evaluate its validity. In this article, we will show you how to interpret the results and generalizability of a clinical decision analysis (Table). As shown in the Figure, decision trees are displayed graphically, oriented from left to right, with the decision to be analyzed on the left, the compared strategies in the center, and the clinical outcomes on the right. The square box, termed a "decision node," represents
Peroral endoscopic myotomy (POEM) opens the door of third-space endoscopy
Authors: Haruhiro Inoue, Amit Maydeo
Journal: Endoscopy (2019)

Over the last few years, some of the first movers in gastrointestinal endoscopy decided to stretch the limits of the gut lumen. The rapid development of minimally invasive procedures encouraged the concept of natural orifice transluminal endoscopic surgery (NOTES). In 2007, Sumiyama et al. reported, for the first time, access to the peritoneal cavity through the gastric lumen using the mucosal flap valve concept [1]. This technique also enabled successful submucosal endoscopic myotomy to be carried out in living porcine experiments by Pasricha et al. [2].
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)
Authors: Meenakshi Anurag, Mayanne Zhu, Chen Huang, Suhas Vasaikar, Junkai Wang, Jeremy Hoog, Samantha Burugu, Dongxia Gao, Vera Suman, Xiang H Zhang, Bing Zhang, Torsten Nielsen, Matthew J Ellis
Journal: JNCI Journal of the National Cancer Institute (2019)

Unlike estrogen receptor (ER)-negative breast cancer, ER-positive breast cancer outcome is less influenced by lymphocyte content, indicating the presence of immune tolerance mechanisms that may be specific to this disease subset.A supervised analysis of microarray data from the ACOSOG Z1031 (Alliance) neoadjuvant aromatase inhibitor (AI) trial identified upregulated genes in Luminal (Lum) B breast cancers that correlated with AI-resistant tumor proliferation (percentage of Ki67-positive cancer nuclei, Pearson r > 0.4) (33 cases Ki67 > 10% on AI) vs LumB breast cancers that were more AI sensitive (33 cases Ki67 < 10% on AI). Overrepresentation analysis was performed using WebGestalt. All statistical tests were two-sided.Thirty candidate genes positively correlated (r ≥ 0.4) with AI-resistant proliferation in LumB and were upregulated greater than twofold. Gene ontologies identified that the targetable immune checkpoint (IC) components IDO1, LAG3, and PD1 were overrepresented resistance candidates (P ≤ .001). High IDO1 mRNA was associated with poor prognosis in LumB disease (Molecular Taxonomy of Breast Cancer International Consortium, hazard ratio = 1.43, 95% confidence interval = 1.04 to 1.98, P = .03). IDO1 also statistically significantly correlated with STAT1 at protein level in LumB disease (Pearson r = 0.74). As a composite immune tolerance signature, expression of IFN-γ/STAT1 pathway components was associated with higher baseline Ki67, lower estrogen, and progesterone receptor mRNA levels and worse disease-specific survival (P = .002). In a tissue microarray analysis, IDO1 was observed in stromal cells and tumor-associated macrophages, with a higher incidence in LumB cases. Furthermore, IDO1 expression was associated with a macrophage mRNA signature (M1 by CIBERSORT Pearson r = 0.62 ) and by tissue microarray analysis.Targetable IC components are upregulated in the majority of endocrine therapy-resistant LumB cases. Our findings provide rationale for IC inhibition in poor-outcome ER-positive breast cancer.
Philanthropists Fund Johns Hopkins Center for Study of Psychedelics
Authors: Rita Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 15732: Transient Endothelial Dysfunction Induced by Mental Stress Predicts Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
Authors: Bruno B Lima, Muhammad Hammadah, Jeong Hwan Kim, Ibhar Al Mheid, Kobina Wilmot, Irina Uphoff, Salman Sher, Ronnie Ramadan, Amit Shah, Oleksiy Levantsevych, Zakaria Almuwaqqat, Samaah Sullivan, Laura Ward, Michael Kutner, Yi-An Ko, J Douglas Bremner, Arshed Quyyumi, Viola Vaccarino
Journal: Circulation (2018)

Introduction: Even brief episodes of mental stress have been shown to result in transient endothelial dysfunction assessed by brachial artery flow-mediated vasodilation (FMD). However, the prognost...
The Thyrotropin Reference Range Should Be Changed in Older Patients
Authors: Anne R. Cappola
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do-not-intubate orders in patients with acute respiratory failure: a systematic review and meta-analysis
Authors: Michael E. Wilson, Aniket Mittal, Bibek Karki, Claudia C. Dobler, Abdul Wahab, J. Randall Curtis, Patricia J. Erwin, Abdul M. Majzoub, Victor M. Montori, Ognjen Gajic, M. Hassan Murad
Journal: Intensive Care Medicine (2019)
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Authors: Huiying Han, Atul D. Jain, Mihai I. Truica, Javier Izquierdo-Ferrer, Jonathan F. Anker, Barbara Lysy, Vinay Sagar, Yi Luan, Zachary R. Chalmers, Kenji Unno, Hanlin Mok, Rajita Vatapalli, Young A. Yoo, Yara Rodriguez, Irawati Kandela, J. Brandon Parker, Debabrata Chakravarti, Rama K. Mishra, Gary E. Schiltz, Sarki A. Abdulkadir
Journal: Cancer Cell (2019)
Hematopoietic Stem Cell Gene Therapy with Lentiviral Vector in X-Linked Adrenoleukodystrophy
Authors: Patrick Aubourg, Salima Hacein-Bey-Abina, Cynthia Bartholomae, Manfred Schmidt, Ina Kutschera, Michel Vidaud, Liliane Dal-Cortivo, Nizar Mahlaoui, Pierre Frange, Céline Bellesme, Francois Lefrère, Gaelle Dufayet, Alain Fischer, Christof van Kalle, Marina Cavazzana-Calvo, Nathalie Cartier
Journal: Blood (2011)
A near-infrared light-controlled smart nanocarrier with reversible polypeptide-engineered valve for targeted fluorescence-photoacoustic bimodal imaging-guided chemo-photothermal therapy
Authors: Cheng Li, Xiao-Quan Yang, Jie An, Kai Cheng, Xiao-Lin Hou, Xiao-Shuai Zhang, Xian-Lin Song, Kai-Chen Huang, Wei Chen, Bo Liu, Yuan-Di Zhao, Tian-Cai Liu
Journal: Theranostics (2019)

Despite burgeoning development of nanoplatform made in the past few years, it remains a challenge to produce drug nanocarrier that enables requested on/off drug release. Thus, this study aimed to develop an ideal near-infrared light-triggered smart nanocarrier for targeted imaging-guided treatment of cancer that tactfully integrated photothermal therapy with chemotherapy to accurately control drug release time and dosage. Methods: This delivery system was composed of Ag2S QD coating with dendritic mesoporous silica (DMSN), which acted as nanocarrier of doxorubicin localized inside pores. To provide the nanocarrier with controlled release capability, a polypeptide-engineered that structure was reversible to photothermal effect of Ag2S QD, was covalently grafted to the external surface of drug-loaded DMSN. Results: This nanocarrier with the size of 40~60 nm had satisfactory biocompatibility and photothermal conversion efficiency up to 28.35%. Due to acidity-triggered charge reversal of polypeptide, which significantly extended circulation time and improved targeting ability, fluorescence and photoacoustic signals were still obvious at tumor site post-24 h by tail vein injection and chemo-photothermal synergistic therapy obviously enhanced antitumor efficacy. Mild PTT with multiple short-term exposures not only reduced the side effect of overdose drug but also avoided skin damage caused by long-term irradiation. Conclusion: By adjusting irradiation time and on/off cycle, multiple small amount local drug release reduced the side effect of overdose drug and skin damage. This novel approach provided an ideal near-infrared light-triggered nanocarrier with accurate control of area, time, and especially dosage.
Glycomolecules in Echinococcus granulosus cyst fluid inhibit TLR4-mediated inflammatory responses via c-Raf
Authors: Jun Hou, Linlin Li, Dan Dong, Lianghai Wang, Xian Wang, Kun Yang, Xiaodan Xu, Congzhe Chen, Xiangwei Wu, Xueling Chen
Journal: Cellular and Molecular Immunology (2019)